Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia

被引：3
作者：
Ercaliskan, Abdulkadir [1 ]
Eskazan, Ahmet Emre [1 ]
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Div Hematol, Dept Internal Med, TR-34303 Istanbul, Turkey
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 03期
关键词：
adverse event; bosutinib; chronic myeloid leukemia; comorbidity; imatinib; tyrosine kinase inhibitor; KINASE INHIBITOR TKI; IMATINIB; DASATINIB; DISCONTINUATION; NILOTINIB; THERAPY; CML;
D O I：
10.2217/fon-2020-0006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4425 / 4428
页数：4
相关论文
共 23 条
[1]   Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience [J].
Alfayez, Mansour ;
Kantarjian, Hagop M. ;
Kadia, Tapan M. ;
Garcia-Manero, Guillermo ;
Ravandi, Farhad ;
Borthakur, Gautam ;
DiNardo, Courtney D. ;
Rios, Mary B. ;
Jabbour, Elias J. ;
Cortes, Jorge E. .
BLOOD, 2018, 132
[2]  
[Anonymous], 2016, Expert Rev Qual Life Cancer Care
[3]  
[Anonymous], BOS BOS PRESCR INF
[4]   Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia [J].
Cortes, Jorge E. ;
Muresan, Bogdan ;
Mamolo, Carla ;
Cappelleri, Joseph C. ;
Crescenzo, Rocco J. ;
Su, Yun ;
Gambacorti-Passerini, Carlo ;
Heeg, Bart ;
Smith, B. Douglas .
CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (09) :1615-1622
[5]   Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial [J].
Cortes, Jorge E. ;
Gambacorti-Passerini, Carlo ;
Deininger, Michael W. ;
Mauro, Michael J. ;
Chuah, Charles ;
Kim, Dong-Wook ;
Dyagil, Irina ;
Glushko, Nataliia ;
Milojkovic, Dragana ;
le Coutre, Philipp ;
Garcia-Gutierrez, Valentin ;
Reilly, Laurence ;
Jeynes-Ellis, Allison ;
Leip, Eric ;
Bardy-Bouxin, Nathalie ;
Hochhaus, Andreas ;
Brummendorf, Tim H. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) :231-+
[6]   Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib [J].
Cortes, Jorge E. ;
Khoury, Hanna J. ;
Kantarjian, Hagop M. ;
Lipton, Jeff H. ;
Kim, Dong-Wook ;
Schafhausen, Philippe ;
Matczak, Ewa ;
Leip, Eric ;
Noonan, Kay ;
Bruemmendorf, Tim H. ;
Gambacorti-Passerini, Carlo .
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) :1206-1214
[7]   Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial [J].
Cortes, Jorge E. ;
Kim, Dong-Wook ;
Kantarjian, Hagop M. ;
Bruemmendorf, Tim H. ;
Dyagil, Irina ;
Griskevicius, Laimonas ;
Malhotra, Hemant ;
Powell, Christine ;
Gogat, Karin ;
Countouriotis, Athena M. ;
Gambacorti-Passerini, Carlo .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3486-3492
[8]   Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest? [J].
Eskazan, Ahmet Emre .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (10) :2241-2243
[9]   Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes? [J].
Eskazan, Ahmet Emre .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (08) :1635-1638
[10]   Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good? [J].
Eskazan, Ahmet Emre ;
Ozmen, Deniz .
EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (07) :583-586
123